$679 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 99 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMCR | IMMUNOCORE HLDGS PLCads | $24,319,776 | +21.3% | 405,600 | 0.0% | 3.58% | +19.8% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $23,862,537 | +14.5% | 2,651,393 | 0.0% | 3.51% | +13.1% | |
| AXSM | AXSOME THERAPEUTICS INC | $22,995,200 | +16.5% | 320,000 | 0.0% | 3.38% | +15.1% | |
| ITCI | INTRA-CELLULAR THERAPIES INC | $18,996,000 | +16.9% | 300,000 | 0.0% | 2.80% | +15.5% | |
| NYCB | NEW YORK CMNTY BANCORP INC | $18,058,184 | +24.3% | 1,606,600 | 0.0% | 2.66% | +22.9% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $16,484,686 | -6.5% | 692,925 | 0.0% | 2.43% | -7.6% | |
| BGNE | BEIGENE LTDsponsored adr | $15,155,500 | -17.3% | 85,000 | 0.0% | 2.23% | -18.3% | |
| PCVX | VAXCYTE INC | $14,982,000 | +33.2% | 300,000 | 0.0% | 2.21% | +31.7% | |
| LLY | LILLY ELI & CO | $14,069,400 | +36.6% | 30,000 | 0.0% | 2.07% | +34.9% | |
| AZN | ASTRAZENECA PLCsponsored adr | $12,166,900 | +3.1% | 170,000 | 0.0% | 1.79% | +1.9% | |
| ALT | ALTIMMUNE INC | $9,707,500 | -16.4% | 2,750,000 | 0.0% | 1.43% | -17.4% | |
| ZYMEWORKS DEL INC | $9,504,000 | -4.4% | 1,100,000 | 0.0% | 1.40% | -5.6% | ||
| THIRD HARMONIC BIO INC | $8,658,000 | +16.7% | 1,800,000 | 0.0% | 1.28% | +15.4% | ||
| KNSA | KINIKSA PHARMACEUTICALS LTD | $8,448,000 | +30.9% | 600,000 | 0.0% | 1.24% | +29.3% | |
| IONS | IONIS PHARMACEUTICALS INC | $8,206,000 | +14.8% | 200,000 | 0.0% | 1.21% | +13.4% | |
| BIO | BIO RAD LABS INCcl a | $6,065,920 | -20.9% | 16,000 | 0.0% | 0.89% | -21.8% | |
| C | CITIGROUP INC | $4,604,000 | -1.8% | 100,000 | 0.0% | 0.68% | -3.0% | |
| ENZ | ENZO BIOCHEM INC | $4,232,000 | -24.3% | 2,300,000 | 0.0% | 0.62% | -25.2% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $3,876,000 | +31.7% | 300,000 | 0.0% | 0.57% | +30.1% | |
| GLPG | GALAPAGOS NVspon adr | $3,645,169 | +5.2% | 89,650 | 0.0% | 0.54% | +4.1% | |
| INSM | INSMED INC | $3,506,883 | +23.8% | 166,203 | 0.0% | 0.52% | +22.3% | |
| BIOHAVEN LTD | $3,348,800 | +75.1% | 140,000 | 0.0% | 0.49% | +73.0% | ||
| FATE | FATE THERAPEUTICS INC | $3,332,000 | -16.5% | 700,000 | 0.0% | 0.49% | -17.5% | |
| SBTX | ARS PHARMACEUTICALS INC | $2,743,402 | +2.9% | 409,463 | 0.0% | 0.40% | +1.8% | |
| CVBF | CVB FINL CORP | $2,656,000 | -20.4% | 200,000 | 0.0% | 0.39% | -21.3% | |
| ESPR | ESPERION THERAPEUTICS INC NE | $2,571,500 | -12.6% | 1,850,000 | 0.0% | 0.38% | -13.5% | |
| 2SEVENTY BIO INC | $2,530,000 | -0.8% | 250,000 | 0.0% | 0.37% | -2.1% | ||
| AMYLYX PHARMACEUTICALS INC | $2,157,000 | -26.5% | 100,000 | 0.0% | 0.32% | -27.2% | ||
| BKU | BANKUNITED INC | $2,155,000 | -4.6% | 100,000 | 0.0% | 0.32% | -5.7% | |
| EQC | EQUITY COMWLTH | $2,026,000 | -2.2% | 100,000 | 0.0% | 0.30% | -3.6% | |
| ARVN | ARVINAS INC | $1,985,600 | -9.2% | 80,000 | 0.0% | 0.29% | -10.4% | |
| SFBS | SERVISFIRST BANCSHARES INC | $1,227,600 | -25.1% | 30,000 | 0.0% | 0.18% | -25.8% | |
| ATHA | ATHIRA PHARMA INC | $1,040,509 | +18.0% | 352,715 | 0.0% | 0.15% | +16.8% | |
| NXTC | NEXTCURE INC | $720,000 | +21.6% | 400,000 | 0.0% | 0.11% | +20.5% | |
| TANGO THERAPEUTICS INC | $664,000 | -15.9% | 200,000 | 0.0% | 0.10% | -16.9% | ||
| PASG | PASSAGE BIO INC | $282,390 | -1.7% | 300,000 | 0.0% | 0.04% | -2.3% | |
| ACELRX PHARMACEUTICALS INC | $216,450 | +68.7% | 195,000 | 0.0% | 0.03% | +68.4% | ||
| NKTR | NEKTAR THERAPEUTICS | $80,298 | -18.2% | 139,600 | 0.0% | 0.01% | -20.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.